Geovax Labs (GOVX)

First Gedeptin Data From Phase 1/2 Presented


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
July 11, 2023
Report ID: 25955
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Geovax Labs
Geovax Labs
Healthcare
Biotechnology
Ticker
GOVX
Current Price
$0.5177 2.29%
Market Cap
$13.7M
Price Target
Refer to Report
Volume
125.8K
52wk Range
$0.5055 - $1.39
Related Research Reports
8/10/2023

2Q23 Financial Report Reviews Progress During The Quarter
2Q23 Financial Report Reviews Progress During The Quarter (GOVX)
7/24/2023

New Patent Covering Ebolavirus Vaccine Issued
New Patent Covering Ebolavirus Vaccine Issued (GOVX)
7/20/2023

Phase 2 Study For COVID-19 Booster In CLL Patients Begins
Phase 2 Study For COVID-19 Booster In CLL Patients Begins (GOVX)
7/11/2023

First Gedeptin Data From Phase 1/2 Presented
First Gedeptin Data From Phase 1/2 Presented (GOVX)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.